Navigation Links
Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
Date:5/5/2008

Preclinical findings of amylin/leptin synergy and translational Phase 2A clinical results published online today in Proceedings of the National

Academy of Sciences of the United States of America

SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced the initiation of a Phase 2B clinical study evaluating various dosing combinations of pramlintide, an analog of the natural hormone amylin, and recombinant human leptin (r-metHuLeptin; metreleptin) for the treatment of obesity. The objective of this dose-ranging study is to support dose selection for Phase 3, and to inform the ongoing development of a convenient delivery system for this combination regimen. The six-month, randomized, double-blind, placebo-controlled multi-center study will enroll approximately 600 overweight and obese subjects and is expected to complete in mid-2009.

"There is a tremendous medical need and market demand for a weight loss product that meets both safety and efficacy expectations of patients and physicians, and we believe that our integrated neurohormonal approach to obesity holds great promise for achieving this profile," stated Christian Weyer, M.D., Vice President of Clinical Research, Amylin Pharmaceuticals. "Building upon the positive results of our translational research program published today in PNAS, and the extensive clinical experience with both pramlintide and metreleptin as monotherapies, the newly initiated Phase 2B study will bring us one step closer to our goal of offering obese individuals a safe and effective therapy that results in meaningful weight loss."

The Phase 2B study will include a broad range of overweight and obese subjects (body mass index 27 to 45 k
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
2. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
3. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
4. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
5. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
6. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
9. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
10. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
11. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... ROCHESTER, N.Y. , July 23, 2014 ... VSCP ), a leading provider of clinical trial ... , 48, has been named president and chief executive ... of Directors in August 2013 and has held the ... October 25, 2013. Dr. Charles E. ...
(Date:7/23/2014)... 23, 2014 Research and Markets ... in Consumer Healthcare by Application, Sensor Type & by ... 2020" report to their offering. ... an increasing momentum for consumer healthcare monitoring and sensing ... consumer healthcare will lessen the healthcare cost of the ...
(Date:7/23/2014)... MOUNTAIN VIEW, Calif. , July 23, ... in translational preclinical research, today unveiled their new logo ... the transformation of Surpass, corporate culture to one where ... customers. This press release comes on the heels of ... added to the Silicon Valley Team:  David Craig, a ...
Breaking Medicine Technology:Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 2Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 3SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3
... Sept. 30, 2011 Haemonetics Corporation (NYSE: ... quarter of its 2012 fiscal year on October 31, ... hold a webcast to discuss and answer questions about ... 31, 2011. Webcast Link: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=4204617 ...
... Sept. 29, 2011 Boston Scientific Corporation (NYSE: ... ( NE ural C ardiac T her A ... a prospective, randomized, international clinical feasibility study designed to assess ... heart failure patients.  The study will evaluate 96 patients with ...
Cached Medicine Technology:Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 2Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 3Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 4
(Date:7/23/2014)... Ft. Lauderdale, FL (PRWEB) July 23, 2014 ... and the largest online retailer of nutritional supplements, has ... Supplement Awards. BPI SPORTS , the fastest growing ... the following categories: , Brand of the Year, Best ... of the Year, Protein Powder of the year - ...
(Date:7/23/2014)... syndrome ( FXS ) is a genetic disorder that ... the autistic spectrum, as well as cognitive deficits. It ... and the most common cause of autism. , Now ... published a study that sheds light on ... today (July 23) in the Journal of Neuroscience ...
(Date:7/23/2014)... disorders of obesity and dementia reside in the brain, ... Behavioral Neuroscience. In the paper, researchers make the case ... the brain responsible for memory and learning. Furthermore, treatments ... in reducing certain dementias., "In the struggle to treat ... This is a new way for providers who treat ...
(Date:7/23/2014)... The voice on the recording was low and calm ... he was infected with the human immunodeficiency virus (HIV) that causes ... thing you know I was on the floor flat on my ... hopeful when the recording ended less than 10 minutes later. “Don’t ... because it is just God setting you up for something ...
(Date:7/23/2014)... PA (PRWEB) July 23, 2014 Four ... have been lauded in the latest ranking of the ... Report . Released online today and slated for ... Guide recognizes Allegheny General Hospital (AGH), Forbes Hospital, Saint ... medical centers across multiple clinical specialties. , ...
Breaking Medicine News(10 mins):Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 2Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 3Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 3Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 2Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 3
... antidepressant Lexapro permitted by Food and Drug Administration, U.S.// ... FDA to sell escitalopram, a generic immitator of the oral ... drug are retained by the Forest Labs till March 2012 ... This copyright is illogical as per Teva. ,Lundbeck, ...
... that volunteers distributing condoms in the province would no longer ... rates of teenage pregnancies//. The trust said that only authorized ... protection measure. ,"My concern is that child ... commented Dr Dean Marshall, deputy chairman of the BMA's Scottish ...
... statement has said that drug maker Cipla Ltd. has ... nevirapine// that is to be marketed in a tablet ... similar approval for ondansetron in the injection form. ... following chemotherapy or radiation therapy for cancer. The drug ...
... increased blood pressure. But according to a recent study ... in giving them an uninterrupted sleep at the same ... results were presented at the American Thoracic Society International ... person's physical health, and this study shows once again ...
... presented at the American Thoracic Society International Conference, it was ... in lower lung function. The study of 2,112 adolescents ages ... of vitamin D, the recommended amount for this age group. ... low dietary intake of vitamin D (157 IU or less ...
... it was found that amino acid, l-cysteine can prevent ... of the cancers occur// in the mouth, pharynx and ... drinking. This results in a strong exposure of the ... research group of Professor Mikko Salaspuro, University of Helsinki ...
Cached Medicine News:Health News:Sleep Apnea Patients Benefit from Breathing Mask 2Health News:Decreased Vitamin D Intake among Teens Results in Decreased Lung Function 2Health News:Finnish research: Cysteine Chewing Gum as a cure for cancers of the mouth 2
Performa uncemented stem....
Standard Erlanger hip stem....
Stability cemented stem....
Porous foundation 470 series....
Medicine Products: